---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000923"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:32:43.260096+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M

## Summary
- Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).
- FY product revenue $9.2M (flat YoY); tests ~24,305 (+1.3%); AUP $378 (-1.0%); gross margin 59.7% (+2.2 ppts).
- Operating expenses Q4 $4.9M (-8% YoY); FY $21.8M (-10% YoY).
- Cash ~$3.7M as of Mar 27, 2025; pending $1.5M ARPA-H milestone; raised $5.75M via convertible notes and ATM.
- New CEO Mike Buhle appointed; ARPA-H $10M award milestone; Ellen Beausang added to Board.

## SEC filing metadata
- accession: 0001641172-25-000923
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/0001641172-25-000923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000164117225000923/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000923
- JSON: https://secwatch.observer/filing/0001641172-25-000923.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.